Effect of Selenium Supplementation on Influenza Vaccination

Status Completed

Clinical Trial Summary

The study is designed to assess whether selenium supplementation can boost the immunity response to influenza vaccination in healthy adults. This is a randomized, prospective study enrolling a total of 60 healthy subjects, 18-55 years old.

Clinical Trial Description

Background: Selenium is an essential trace element required for human health and wellbeing. Despite mouse studies and human clinical trial suggest selenium supplementation might enhance immunity, little is known for the effects of selenium supplementation on humoral immunity. Vaccination is the most effective medical intervention to prevent infections and to reduce disability and mortality associated with infectious disease. However, some individuals, in healthy or disease conditions, mount less effective humoral immune responses to vaccination. Therefore, new strategy to enhance humoral immunity upon vaccination is highly sought after. Using mouse models, we have observed that selenium supplementation significantly increased antigen-specific antibody responses. Thus, we hypothesize that selenium supplementation may be beneficial in enhancing humoral immunity in humans.

Objectives: To investigate whether selenium supplementation will boost the humoral response to influenza vaccination in healthy adults.

Design and trial size: This is a randomized prospective study. A total of 60 healthy subjects, 18-55 years old, will be enrolled in this study.

Intervention and duration: The enrolled subjects will be randomized into selenium supplementation and control group. The selenium supplementation group will receive 200 μg selenium daily by taking two selenium-enriched yeast tablets (SelenoPrecise®, Pharma Nord) once daily for 60 days. The control group will not receive selenium supplementation. Thirty days after allocation, both groups will receive standard seasonal influenza vaccination for the 2019-2020 season. Peripheral blood samples will be collected at baseline (day 0, prior to treatment), day 30, day 37 (7 days after vaccination) and day 60 (30 days after vaccination). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04188483
Study type	Interventional
Source	Huazhong University of Science and Technology
Contact
Status	Completed
Phase	N/A
Start date	October 15, 2019
Completion date	February 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05509270` - Efficacy of Communication Modalities for Promoting Flu Shots	N/A
Recruiting	`NCT05479370` - Immunogenicity Trial of 3 Influenza Vaccines	Phase 3
Completed	`NCT03637036` - An Improvement Project Around Staffs' Influenza Vaccine Uptake	N/A
Completed	`NCT01942824` - Adult Influenza Vaccination Text Message Reminders	N/A
Completed	`NCT01009645` - The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination	N/A
Completed	`NCT05783713` - Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study
Recruiting	`NCT03346772` - Study of Immune Responses to Influenza Vaccination	Phase 4
Completed	`NCT03104790` - Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls	Phase 4
Completed	`NCT05836818` - PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED	N/A
Completed	`NCT05785078` - Evaluation of a Flu Vaccination Program Directed at Pregnant Women Assisted at a Research Hospital in Italy.
Completed	`NCT04568785` - Effectiveness of a Brief Intervention for Acceptance of Influenza Vaccine in the Primary Care Setting	N/A
Completed	`NCT03167593` - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.	Phase 2
Completed	`NCT01233804` - Opting In vs Opting Out	N/A
Completed	`NCT04494581` - GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
Recruiting	`NCT04367883` - Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Completed	`NCT06300242` - Incentives for Influenza Vaccination	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.